Provepharm SAS

Methylene Blue Injection, USP (Nexus Pharmaceutical, LLC) received FDA approval for treating acquired methemoglobinemia (MetHb). This condition, characterized by abnormal methemoglobin production, can be inherited or acquired through medication exposure. Methylene Blue reduces oxidized hemoglobin (Fe3+) to its functional form (Fe2+), enhancing oxygen-binding capacity. The approval expands treatment options for MetHb, improving patient outcomes.